Lancet 2011-12-17
Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
ABSTRACT
BACKGROUND
Whether the addition of radiation therapy (RT) improves overall survival in men with locally advanced prostate cancer managed with androgen deprivation therapy (ADT) is unclear. Our aim was to compare outcomes in such patients with locally advanced prostate cancer.
METHODS
Patients with: locally advanced (T3 or T4) prostate cancer (n=1057); or organ-confined disease (T2) with either a prostate-specific antigen (PSA) concentration more than 40 ng/mL (n=119) or PSA concentration more than 20 ng/mL and a Gleason score of 8 or higher (n=25), were randomly assigned (done centrally with stratification and dynamic minimisation, not masked) to receive lifelong ADT and RT (65-69 Gy to the prostate and seminal vesicles, 45 Gy to the pelvic nodes). The primary endpoint was overall survival. The results presented here are of an interim analysis planned for when two-thirds of the events for the final analysis were recorded. All efficacy analyses were done by intention to treat and were based on data from all patients. This trial is registered at controlledtrials.com as ISRCTN24991896 and Clinicaltrials.gov as NCT00002633.
RESULTS
Between 1995 and 2005, 1205 patients were randomly assigned (602 in the ADT only group and 603 in the ADT and RT group); median follow-up was 6·0 years (IQR 4·4-8·0). At the time of analysis, a total of 320 patients had died, 175 in the ADT only group and 145 in the ADT and RT group. The addition of RT to ADT improved overall survival at 7 years (74%, 95% CI 70-78 vs 66%, 60-70; hazard ratio [HR] 0·77, 95% CI 0·61-0·98, p=0·033). Both toxicity and health-related quality-of-life results showed a small effect of RT on late gastrointestinal toxicity (rectal bleeding grade >3, three patients (0·5%) in the ADT only group, two (0·3%) in the ADT and RT group; diarrhoea grade >3, four patients (0·7%) vs eight (1·3%); urinary toxicity grade >3, 14 patients (2·3%) in both groups).
INTERPRETATION
The benefits of combined modality treatment--ADT and RT--should be discussed with all patients with locally advanced prostate cancer.
FUNDING
Canadian Cancer Society Research Institute, US National Cancer Institute, and UK Medical Research Council.
Related Questions
If so, what dose? What if there is positive a PA lymph node but no signs of distal mets?
New comment by Radiation Oncologist at Sierra Nevada Cancer Center ( November 4, 2018)
Please provide More detail about the SIB dose and fractionation employed at MDA for positive pelvic nodes based on size before and after initial ADT.
Also, what extent of p...
Is there an upper limit to offer definitive RT? Is it possible to have a PSA of 100-500 and still have only local disease?
New answer by Radiation Oncologist at Radiation Medical Group (April 25, 2017)
PSA > 10,000 ng/mL would be a valid indication not to proceed . . . Otherwise, I would not let a case be ruled by labs in the absence of definitive radiological or pat...
How would a much higher risk cancer affect decision making? How would you treat him?
New answer by Radiation Oncologist at Virginia Commonwealth University Medical Center (February 1, 2020)
I agree with @Daniel E. Spratt. The lung cancer represents the greater threat to the patient's life expectancy. I'll generally try to wait 2 years, as most lung cancer recurre...
NCCN guidelines recommend pelvic RT for N+, but what is the hard evidence for this?
New comment by Radiation Oncologist at The Oregon Clinic-Radiation Oncology West ( June 12, 2020)
I agree with all comments above. The Australian and New Zealand Radiation Oncology GU group recently published a nice review of radiotherapy recommendations for node-positive ...
New comment by Radiation Oncologist at Mon Health ( September 1, 2023)
Well said, my friend.